FDA MDR COST ESTIMATES EXPECTED TO BE FOCUS OF REP. UPTON'S NEXT ROUND OF QUESTIONS ON MDR RULE; AGENCY STANDS BY $600 PER-ESTABLISHMENT FIGURE
This article was originally published in The Gray Sheet
Executive Summary
Rep. Fred Upton (R-Mich.) is expected to continue scrutinizing FDA's cost estimates for complying with the medical device reporting rule. Upton is drafting a letter to the agency that will express dissatisfaction with several responses FDA gave to a series of MDR-related questions posed by the legislator in May. One of the likely focal points of the upcoming letter will be the agency's defense of its cost estimates.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.